

# Giovanni Ferrara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4218839/publications.pdf>

Version: 2024-02-01

84

papers

3,849

citations

172386

29

h-index

123376

61

g-index

89

all docs

89

docs citations

89

times ranked

4203

citing authors

#	ARTICLE	IF	CITATIONS
1	Chapter 15: Monitoring tuberculosis program performance. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 229-241.	0.2	2
2	COVID-19 hospitalization is associated with pulmonary/diffusion abnormalities but not post-acute sequelae of COVID-19 severity. Journal of Internal Medicine, 2022, 291, 694-697.	2.7	4
3	Reference equations for oscillometry and their differences among populations: a systematic scoping review. European Respiratory Review, 2022, 31, 220021.	3.0	3
4	Use of Immunoglobulins in the Prevention of Viral Infections. , 2021, , 267-280.		1
5	Disseminated TB: still being missed and misunderstood. International Journal of Tuberculosis and Lung Disease, 2021, 25, 255-257.	0.6	0
6	Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respiratory Research, 2021, 22, 109.	1.4	65
7	Exertional intolerance and dyspnea with preserved lung function: an emerging long COVID phenotype?. Respiratory Research, 2021, 22, 222.	1.4	25
8	Macrolides versus placebo for chronic asthma. The Cochrane Library, 2021, 2021, CD002997.	1.5	4
9	What Patients With Idiopathic Pulmonary Fibrosis and Caregivers Want: Filling the Gaps With Patient Reported Outcomes and Experience Measures. American Journal of Medicine, 2020, 133, 281-289.	0.6	36
10	RA-ILD: does more detailed radiological classification add something to our knowledge of this condition?. Journal of Thoracic Disease, 2020, 12, 2993-2995.	0.6	2
11	Six-minute walking test outweighs other predictors of mortality in idiopathic pulmonary fibrosis. A real-life study from the Swedish IPF registry. Respiratory Medicine: X, 2020, 2, 100017.	1.4	8
12	Early referral to palliative care in IPF – pitfalls and opportunities in clinical trials. Respiratory Research, 2020, 21, 174.	1.4	2
13	Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015. Respiratory Medicine, 2019, 155, 72-78.	1.3	18
14	Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden. Pulmonary Therapy, 2019, 5, 55-68.	1.1	12
15	Pulmonary outcomes in adults with a history of Bronchopulmonary Dysplasia differ from patients with asthma. Respiratory Research, 2019, 20, 102.	1.4	31
16	An Atypical Case of Idiopathic Pulmonary Fibrosis in a Patient from Africa. Medicina (Lithuania), 2019, 55, 67.	0.8	0
17	Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden. BMC Pulmonary Medicine, 2019, 19, 222.	0.8	25
18	Autoantibodies in patients with idiopathic pulmonary fibrosis. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
19	Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions. European Respiratory Review, 2018, 27, 170076.	3.0	40
20	Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries. Multidisciplinary Respiratory Medicine, 2018, 13, 14.	0.6	22
21	Latent tuberculous infection among foreign-born individuals applying to shelters in the metropolitan area of Milan. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1160-1165.	0.6	5
22	Pulmonary outcomes in adults with a history of Bronchopulmonary Dysplasia (BPD). , 2018, , .		1
23	Forced vital capacity, total lung capacity and diffusion capacity in idiopathic pulmonary fibrosis. , 2018, , .		0
24	Disease characteristics and outcomes in a Swedish cohort of patients with pulmonary fibrosis (PF). , 2018, , .		0
25	Pirfenidone use in a Swedish cohort of patients with pulmonary fibrosis (PF). , 2018, , .		0
26	Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays. International Journal of Infectious Diseases, 2017, 56, 155-166.	1.5	9
27	Humoral immune profiling of mycobacterial antigen recognition in sarcoidosis and Löfgren's syndrome using high-content peptide microarrays. International Journal of Infectious Diseases, 2017, 56, 167-175.	1.5	13
28	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine, 2017, 5, 591-598.	5.2	71
29	Lung function development after preterm birth in relation to severity of Bronchopulmonary dysplasia. BMC Pulmonary Medicine, 2017, 17, 97.	0.8	43
30	Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma. Multidisciplinary Respiratory Medicine, 2017, 12, 16.	0.6	21
31	Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. Journal of Internal Medicine, 2017, 281, 149-166.	2.7	27
32	Idiopathic pulmonary fibrosis in Finland and Sweden: differences in the performance of two similar health care systems. , 2017, , .		0
33	Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry. European Clinical Respiratory Journal, 2016, 3, 31090.	0.7	37
34	Need for combined interventions and operational research to tackle tuberculous meningitis. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1423-1423.	0.6	0
35	Inspiratory muscle training in addition to physical exercise for idiopathic pulmonary fibrosis. , 2016, , .		2
36	Long term pulmonary outcome after mild to severe bronchopulmonary dysplasia. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
37	Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma. , 2016, , .		0
38	Macrolides for chronic asthma. The Cochrane Library, 2015, , CD002997.	1.5	103
39	Recurrent respiratory infections and unusual radiology: a woman with Kartagener's syndrome. BMJ Case Reports, 2015, 2015, bcr2015211650.	0.2	1
40	Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. Internal and Emergency Medicine, 2015, 10, 401-411.	1.0	37
41	Extra-pulmonary tuberculosis and Xpert® MTB/RIF: all about meta-analyses?. International Journal of Tuberculosis and Lung Disease, 2015, 19, 254-254.	0.6	1
42	T-Cell Therapy: Options for Infectious Diseases: Table 1.. Clinical Infectious Diseases, 2015, 61, S217-S224.	2.9	42
43	Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis. BMC Immunology, 2015, 16, 40.	0.9	22
44	ADVANCES IN THERAPIES FOR INTERSTITIAL LUNG DISEASES. , 2015, , 257-282.		0
45	No association between Birt-Hogg-Dubé syndrome skin fibrofolliculomas and the first 10 described human polyomaviruses or human papillomaviruses. Virology, 2014, 468-470, 244-247.	1.1	3
46	Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respiratory Medicine, 2014, 2, 108-122.	5.2	115
47	Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. The Cochrane Library, 2013, 2013, CD009019.	1.5	57
48	Isoniazid preventive treatment: predictors of adverse events and treatment completion. International Journal of Tuberculosis and Lung Disease, 2013, 17, 903-908.	0.6	25
49	Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence: Table 1. European Respiratory Journal, 2013, 42, 288-290.	3.1	45
50	Intra-abdominal bleeding during treprostinil infusion in a patient with pulmonary arterial hypertension. BMJ Case Reports, 2013, 2013, bcr2013008677-bcr2013008677.	0.2	4
51	Chronic empyema: importance of preventing complications in the management of pleural effusions. BMJ Case Reports, 2013, 2013, bcr2013200454-bcr2013200454.	0.2	1
52	Risk factors associated with pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 2012, 18, 233-240.	1.2	60
53	Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections. American Journal of Medicine, 2012, 125, 1036.e1-1036.e8.	0.6	29
54	Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. European Respiratory Journal, 2012, 40, 1430-1442.	3.1	346

#	ARTICLE	IF	CITATIONS
55	Trends and challenges in tuberculosis in a medium-sized southern European setting [Notes from the field]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 645-648.	0.6	5
56	Interferon- $\gamma$ release assays for the diagnosis of latent <i>Mycobacterium tuberculosis</i> infection: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2011, 37, 88-99.	3.1	490
57	Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. <i>The Cochrane Library</i> , 2011, , CD004106.	1.5	15
58	Xpert MTB/RIF test for tuberculosis. <i>Lancet</i> , The, 2011, 378, 482.	6.3	3
59	Tuberculosis in prisons in sub-Saharan Africa “the need for improved health services, surveillance and control. <i>Tuberculosis</i> , 2011, 91, 173-178.	0.8	73
60	A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with <i>M. tuberculosis</i> . <i>Tuberculosis</i> , 2011, 91, 260-267.	0.8	113
61	A Decade of Interferon- $\gamma$ Release Assays: Quest for the Holy Grail to Diagnose Latent Infection with <i>Mycobacterium tuberculosis</i> ?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1732-1732.	2.5	1
62	Tuberculosis in prisons: anatomy of global neglect. <i>European Respiratory Journal</i> , 2011, 38, 752-754.	3.1	39
63	Screening of immigrants in the UK for latent tuberculosis. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 483-486.	1.0	2
64	TB or not TB: update from the ERS Respiratory Infection Assembly 10. <i>European Respiratory Journal</i> , 2010, 36, 665-670.	3.1	5
65	Interferon- $\gamma$ -Release Assays Detect Recent Tuberculosis Re-Infection in Elderly Contacts. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 669-677.	1.0	21
66	Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients. <i>Chest</i> , 2009, 136, 198-204.	0.4	137
67	Exploring the immune response against <i>Mycobacterium tuberculosis</i> for a better diagnosis of the infection. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2009, 57, 425-433.	1.0	16
68	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. <i>European Respiratory Journal</i> , 2009, 33, 871-881.	3.1	163
69	<i>Mycobacterium tuberculosis</i> Induces CCL18 Expression in Human Macrophages. <i>Scandinavian Journal of Immunology</i> , 2008, 68, 668-674.	1.3	24
70	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. <i>European Respiratory Journal</i> , 2008, 31, 1155-1159.	3.1	131
71	Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT. $\cdot$ assay. <i>Expert Review of Respiratory Medicine</i> , 2008, 2, 253-260.	1.0	12
72	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2008, 31, 904-905.	3.1	67

#	ARTICLE	IF	CITATIONS
73	Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. , 2008, , CD004106.		27
74	Clinical and operational value of the extensively drug-resistant tuberculosis definition. European Respiratory Journal, 2007, 30, 623-626.	3.1	179
75	Extensively Drug-resistant Tuberculosis, Italy and Germany. Emerging Infectious Diseases, 2007, 13, 780-782.	2.0	96
76	Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet, The, 2006, 367, 1328-1334.	6.3	468
77	Blood tests for diagnosis of tuberculosis â€“ Authors' reply. Lancet, The, 2006, 368, 282-283.	6.3	15
78	Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respiratory Medicine, 2006, 100, 1566-1572.	1.3	42
79	Community Acquired Pneumonia in Internal Medicine: A One-Year Retrospective Study Based on Pneumonia Severity Index. International Journal of Immunopathology and Pharmacology, 2005, 18, 575-586.	1.0	12
80	Routine Hospital Use of a New Commercial Whole Blood Interferon-Î³ Assay for the Diagnosis of Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 631-635.	2.5	240
81	Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998â€“2000. European Respiratory Journal, 2003, 21, 129-134.	3.1	12
82	Die idiopathische pulmonale Fibrose jenseits der Lunge: Krankheitsmechanismen verstehen, um Diagnose und Therapie zu verbessern. Karger Kompass Pneumologie, 0, , 1-12.	0.0	0
83	Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma. Multidisciplinary Respiratory Medicine, 0, 12, .	0.6	0
84	Persistent dyspnea after COVID-19 is not related to cardiopulmonary impairment; a cross-sectional study of persistently dyspneic COVID-19, non-dyspneic COVID-19 and controls. Frontiers in Physiology, 0, 13, .	1.3	15